Q2 2026 13F · SEC CIK 1831942
Commodore Capital LP
Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $1.7B
- Reported positions
- 33
- Top holdings a year, 3 yrs
- +50.9%
- Assets under management
- $2.4B
Commodore Capital LP is a hedge fund that reported 33 positions worth $1.7B in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Relay Therapeutics Inc (RLAY, 13.4%), Enliven Therapeutics Inc (ELVN, 9.9%), Alkermes PLC (ALKS, 9.4%). A portfolio copying its top holdings returned 50.9% a year over the last 3 years, against 22.3% for the S&P 500.
Commodore Capital LP holdings all 33 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
What Commodore Capital LP bought and sold in Q2 2026, against Q1 2026.
New positions
- TNGX Tango Therapeutics Inc4.2% of 13F
- EDIT Editas Medicine Inc1.7% of 13F
- Inflarx NV1.0% of 13F
- RACC Research Alliance Corp III0.3% of 13F
- VTGN Vistagen Therapeutics Inc0.0% of 13F
Added to
- RLMD Relmada Therapeutics Inc+124.8% shares
- AVTX Avalo Therapeutics Inc+110.8% shares
- EYPT Eyepoint Pharmaceuticals Inc+62.8% shares
- ASMB Assembly Biosciences Inc.+41.5% shares
- ANTX An2 Therapeutics Inc+25.7% shares
- COGT Cogent Biosciences Inc+5.6% shares
Reduced
- NUVL Nuvalent Inc-88.0% shares
- KYMR Kymera Therapeutics Inc-66.7% shares
- SYRE Spyre Therapeutics-55.7% shares
- CLDX Celldex Therapeutics Inc New-49.9% shares
- SABS Sab Biotherapeutics Inc-34.8% shares
- RLAY Relay Therapeutics Inc-29.4% shares
- ALKS Alkermes PLC-28.6% shares
- PHVS Pharvaris N V-25.7% shares
Sold out
- ERAS Erasca, Inc.was 3.0%
- XENE Xenon Pharmaceuticals Incwas 2.8%
- NRIX Nurix Therapeutics Incwas 2.0%
- CRVS Corvus Pharmaceuticals Inc Comwas 1.9%
- SLNO Soleno Therapeutics Incwas 1.3%
- OCUL Ocular Therapeutix Incwas 1.3%
- PALI Palisade Bio Incwas 0.7%
- KPTI Karyopharm Therapeutics Incwas 0.6%
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- +59.0% /yr
- S&P 500 +11.7%
- 3 years
- +50.9% /yr
- S&P 500 +22.3%
- 5 years
- +20.6% /yr
- S&P 500 +10.6%
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $1.7B | 33 |
| Q1 2026 | $1.7B | 36 |
| Q4 2025 | $1.5B | 33 |
| Q3 2025 | $2.0B | 37 |
| Q2 2025 | $1.4B | 33 |
| Q1 2025 | $1.4B | 31 |
| Q4 2024 | $1.4B | 31 |
| Q3 2024 | $1.6B | 36 |
| Q2 2024 | $1.5B | 35 |
| Q1 2024 | $1.5B | 39 |
| Q4 2023 | $1.1B | 32 |
| Q3 2023 | $855.5M | 30 |
Questions about Commodore Capital LP's portfolio
What stocks does Commodore Capital LP own?
Commodore Capital LP's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 33 positions worth $1.7B. The largest are Relay Therapeutics Inc (RLAY) at 13.4%, Enliven Therapeutics Inc (ELVN) at 9.9%, Alkermes PLC (ALKS) at 9.4%, Cogent Biosciences Inc (COGT) at 7.0% and Amylyx Pharmaceuticals Inc (AMLX) at 6.0%.
What did Commodore Capital LP buy last quarter?
In Q2 2026, Commodore Capital LP added a new position in Tango Therapeutics Inc (TNGX), a new position in Editas Medicine Inc (EDIT), a new position in Inflarx NV, a new position in Research Alliance Corp III (RACC), a new position in Vistagen Therapeutics Inc (VTGN), Relmada Therapeutics Inc (RLMD) (+124.8% shares), Avalo Therapeutics Inc (AVTX) (+110.8% shares) and Eyepoint Pharmaceuticals Inc (EYPT) (+62.8% shares), compared with its Q1 2026 filing.
What did Commodore Capital LP sell last quarter?
In Q2 2026, Commodore Capital LP sold all of Erasca, Inc. (ERAS), sold all of Xenon Pharmaceuticals Inc (XENE), sold all of Nurix Therapeutics Inc (NRIX), sold all of Corvus Pharmaceuticals Inc Com (CRVS), sold all of Soleno Therapeutics Inc (SLNO), Nuvalent Inc (NUVL) (-88.0% shares), Kymera Therapeutics Inc (KYMR) (-66.7% shares) and Spyre Therapeutics (SYRE) (-55.7% shares), compared with its Q1 2026 filing.
How has Commodore Capital LP's portfolio performed?
A portfolio copying Commodore Capital LP's 20 largest 13F holdings each quarter, from the day each filing was public, returned +50.9% a year over the last 3 years, against +22.3% for the S&P 500. Over 1 year: +59.0% against +11.7%. Over 5 years: +20.6% a year against +10.6%.
When is Commodore Capital LP's next 13F filing due?
13F filings are due 45 days after each quarter ends. Commodore Capital LP's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.
How much money does Commodore Capital LP manage?
Commodore Capital LP reported $2.4B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $1.7B.